and Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors.

is the causative agent of cutaneous leishmaniasis (CL). No human vaccine is available for CL, and current drug regimens present several drawbacks, such as emerging resistance, severe toxicity, medium effectiveness, and/or high cost. Thus, the need for better treatment options against CL is a priority.

LC-MS/MS determination of d-mannose in human serum as a potential cancer biomarker.

Several metabolites in human serum have been identified as potential cancer biomarkers for early detection. This study focuses on the LC-MS/MS method development and validation of d-mannose in human serum. Surrogate blank serum, coupled with stable isotope d-mannose-C, as internal standard, was used for generating standard curves ranging from 1 to 50μg/mL.

Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic study.

Oncrasins are a class of RNA polymerase II inhibitors. Oncrasin-72 is an indole-3 carbinol analog that has shown to inhibit growth and induce the cell death of various human cancer cell lines. Oncrasin-266, a prodrug of oncrasin-72, has been shown to have improved pharmacokinetic properties and safety than Oncrasin-72.